SCLN Financial Facts

Product sales: 37.2M
Diluted net income per share: -0.08
See Full Income Statement

Accrued and other current liabilities: 29.87M
Total assets: 195.9M
See Full Balance Sheet

SciClone Pharmaceuticals, Inc. (SCLN) Earnings

  |   Expand Research on SCLN
Next EPS Date 11/10/15 *Est. EPS Growth Rate +30.0% *Last Qtr.
Average EPS % Beat Rate +197.9% Revenue Growth Rate +16.6% *Last Qtr.
Average % Move 1-Wk after EPS +8.9% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/10/15 Q215 $0.26$0.12 +$0.14$37.9M$37.27M N/A Details
5/11/15 Q115 $0.19$0.03 +$0.16$33.6M$34M N/A Details
11/10/14 Q314 $0.17$0.12 +$0.05$34.3M$34.9M Details
8/11/14 Q214 $0.20$0.10 +$0.10$32.5M$33.4M Details
5/12/14 Q114 $0.10$0.08 +$0.02$26.6M$32.2M Details
4/1/13 Q413 $0.04$0.12 -$0.08$33.1M$35.3M Details
3/12/14 Q413 $0.08$0.15 -$0.07$32.7M$38.3M Details
11/12/13 Q313 $0.18$0.15 +$0.03$35.2M$39.7M = Details